Clinical Trial

Clinical Trial on the Efficacy of Intralesional Triamcinolone Versus Candida Albicans Antigen in Treating Alopecia Areata

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 21, 2024 (before its estimated July 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
The efficacy of two intralesional treatment modalities for alopecia areata will be determined. Thirty patients over the age of 6 with the diagnosis of alopecia areata on the scalp, with an extension of less than 50%, will be included. A comparison will be made between the effectiveness of intralesional Triamcinolone (standard first-line treatment) and intralesional Candida albicans antigen, with serial clinical and trichoscopic pictures at follow-up to evaluate the clinical response and associated adverse effects.
Trial Details
NCT Number NCT06564805
Lead Sponsor Universidad Autonoma de Nuevo Leon
Conditions Alopecia Areata
Enrollment 30 participants
Start Date 2024-08-20
Primary Completion 2025-07-30 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-08-21